Bolt Biotherapeutics, Inc.
Clinical trials sponsored by Bolt Biotherapeutics, Inc., explained in plain language.
-
New drug combo tested for Tough-to-Treat cancers
Disease control TerminatedThis early-stage study tested a new drug called BDC-1001, both by itself and combined with an existing immunotherapy drug (nivolumab), for people with advanced cancers that have a specific marker called HER2. The main goals were to find safe doses and see if the treatments could …
Phase: PHASE1, PHASE2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
First human test of experimental cancer drug halted early
Disease control TerminatedThis was an early-stage study testing a new drug called BDC-3042, both by itself and combined with an existing immunotherapy (cemiplimab), in people with advanced cancers that had stopped responding to standard treatments. The main goals were to find safe doses and see if the tre…
Phase: PHASE1 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Trial for tough breast cancer cases halted early
Disease control TerminatedThis study tested an experimental drug called BDC-1001, both alone and combined with an existing drug (pertuzumab), for people with advanced HER2-positive breast cancer that had worsened after standard treatments. The goal was to see if the treatment could shrink tumors and was s…
Phase: PHASE2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC